Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis.
Adverse drug event
Hypothyroidism
Meta-analysis
Risk assessment
Roxadustat
Thyroid function
Journal
Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
received:
05
04
2024
accepted:
04
06
2024
medline:
9
6
2024
pubmed:
9
6
2024
entrez:
8
6
2024
Statut:
epublish
Résumé
Based on several case reports and observational studies, there is a growing concern regarding the potential association between roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor, and suppression of thyroid function. In this systematic review and meta-analysis (PROSPERO: CRD42023471516), we aimed to evaluate the relationship between roxadustat use and suppression of thyroid function. We conducted a comprehensive search of MEDLINE via PubMed, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials databases using the search term "roxadustat" to identify all relevant studies. The study population comprised adults with renal anemia who participated in a randomized controlled trial or observational study, with roxadustat as the intervention and a placebo or erythropoiesis-stimulating agent (ESA) as the comparator. The primary outcome was suppression of thyroid function and the secondary outcome was hypothyroidism. A meta-analysis was conducted using the DerSimonian-Laird random effects model based on the size of the intention-to-treat population, and the odds ratio (OR) and 95% confidence interval (CI) were calculated. Two reviewers independently screened the articles, extracted data, and assessed studies using the ROBINS-I tool. Of the six studies eligible for inclusion, a meta-analysis was performed using data from two observational studies comparing roxadustat and ESA. The meta-analysis showed that the incidence of suppression of thyroid function was significantly higher with roxadustat use than with ESA use (OR: 6.45; 95% CI: 3.39-12.27; I Our findings highlighted the importance of monitoring thyroid function in patients treated with roxadustat. The results of this review may enhance the safety of using roxadustat to treat renal anemia through advance recognition of the risk for suppression of thyroid function.
Sections du résumé
BACKGROUND
BACKGROUND
Based on several case reports and observational studies, there is a growing concern regarding the potential association between roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor, and suppression of thyroid function. In this systematic review and meta-analysis (PROSPERO: CRD42023471516), we aimed to evaluate the relationship between roxadustat use and suppression of thyroid function.
METHODS
METHODS
We conducted a comprehensive search of MEDLINE via PubMed, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials databases using the search term "roxadustat" to identify all relevant studies. The study population comprised adults with renal anemia who participated in a randomized controlled trial or observational study, with roxadustat as the intervention and a placebo or erythropoiesis-stimulating agent (ESA) as the comparator. The primary outcome was suppression of thyroid function and the secondary outcome was hypothyroidism. A meta-analysis was conducted using the DerSimonian-Laird random effects model based on the size of the intention-to-treat population, and the odds ratio (OR) and 95% confidence interval (CI) were calculated. Two reviewers independently screened the articles, extracted data, and assessed studies using the ROBINS-I tool.
RESULTS
RESULTS
Of the six studies eligible for inclusion, a meta-analysis was performed using data from two observational studies comparing roxadustat and ESA. The meta-analysis showed that the incidence of suppression of thyroid function was significantly higher with roxadustat use than with ESA use (OR: 6.45; 95% CI: 3.39-12.27; I
CONCLUSIONS
CONCLUSIONS
Our findings highlighted the importance of monitoring thyroid function in patients treated with roxadustat. The results of this review may enhance the safety of using roxadustat to treat renal anemia through advance recognition of the risk for suppression of thyroid function.
Identifiants
pubmed: 38851711
doi: 10.1186/s40780-024-00351-z
pii: 10.1186/s40780-024-00351-z
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30Informations de copyright
© 2024. The Author(s).
Références
Kovesdy CP. Epidemiology of chronic kidney disease: An update 2022. Kidney Int Suppl. 2011;2022(12):7–11.
Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE. 2014;9:e84943.
doi: 10.1371/journal.pone.0084943
pubmed: 24392162
pmcid: 3879360
Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: A review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119:2017–32.
doi: 10.1093/cvr/cvad083
pubmed: 37249051
pmcid: 10478756
Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD anaemia on patients: Incidence, risk factors, and clinical outcomes-A systematic literature review. Int J Nephrol. 2020;2020:7692376.
doi: 10.1155/2020/7692376
pubmed: 32665863
pmcid: 7349626
Locatelli F, Minutolo R, De Nicola L, Del Vecchio L. Evolving strategies in the treatment of anaemia in chronic kidney disease: The HIF-prolyl hydroxylase inhibitors. Drugs. 2022;82:1565–89.
doi: 10.1007/s40265-022-01783-3
pubmed: 36350500
pmcid: 9645314
Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol. 2020;31:456–68.
doi: 10.1681/ASN.2019020213
pubmed: 32041774
pmcid: 7062209
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67:912–24.
doi: 10.1053/j.ajkd.2015.12.020
pubmed: 26846333
Ogawa C, Tsuchiya K, Maeda K. Hypoxia-inducible factor prolyl hydroxylase inhibitors and iron metabolism. Int J Mol Sci. 2023;24:3037.
doi: 10.3390/ijms24033037
pubmed: 36769359
pmcid: 9917929
Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, et al. Novel anemia therapies in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023;104:655–80.
doi: 10.1016/j.kint.2023.05.009
pubmed: 37236424
Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant. 2010;25:3701–6.
doi: 10.1093/ndt/gfq287
pubmed: 20507852
Zheng L, Tian J, Liu D, Zhao Y, Fang X, Zhang Y, et al. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:919–32.
doi: 10.1111/bcp.15055
pubmed: 34428860
Ichii M, Mori K, Miyaoka D, Sonoda M, Tsujimoto Y, Nakatani S, et al. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol. 2021;22:104.
doi: 10.1186/s12882-021-02304-2
pubmed: 33743638
pmcid: 7981856
Tokuyama A, Kadoya H, Obata A, Obata T, Sasaki T, Kashihara N. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021;14:1472–4.
doi: 10.1093/ckj/sfab007
pubmed: 33959275
pmcid: 8087136
Kouki Y, Okada N, Saga K, Ozaki M, Saisyo A, Kitahara T. Disproportionality analysis on hypothyroidism with roxadustat using the Japanese Adverse Drug Event Database. J Clin Pharmacol. 2023;63:1141–6.
doi: 10.1002/jcph.2300
pubmed: 37408303
Tanaka H, Tani A, Onoda T, Ishii T. Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: An analysis of the Japanese Pharmacovigilance Database. In Vivo. 2024;38:917–22.
doi: 10.21873/invivo.13519
pubmed: 38418113
pmcid: 10905430
Haraguchi T, Hamamoto Y, Kuwata H, Yamazaki Y, Nakatani S, Hyo T, et al. Effect of roxadustat on thyroid function in patients with renal anemia. J Clin Endocrinol Metab. 2023;109:e69–75.
doi: 10.1210/clinem/dgad483
pubmed: 37597171
Ma Y, Freitag P, Zhou J, Brune B, Frede S, Fandrey J. Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. Am J Physiol Regul Integr Comp Physiol. 2004;287:R600–7.
doi: 10.1152/ajpregu.00115.2004
pubmed: 15155277
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLOS Med. 2009;6:e1000100.
doi: 10.1371/journal.pmed.1000100
pubmed: 19621070
pmcid: 2707010
Sterne JA, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. Robins-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
doi: 10.1136/bmj.i4919
pubmed: 27733354
pmcid: 5062054
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
doi: 10.1016/0197-2456(86)90046-2
pubmed: 3802833
Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30:1665–73.
doi: 10.1093/ndt/gfv302
pubmed: 26238121
pmcid: 4569392
Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6:624–35.
doi: 10.1016/j.ekir.2020.11.034
pubmed: 33732977
Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6:1829–39.
doi: 10.1016/j.ekir.2021.04.007
pubmed: 34307977
pmcid: 8258588
Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, et al. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: Results from the randomized phase 3 Rockies study. J Am Soc Nephrol. 2022;33:850–66.
doi: 10.1681/ASN.2020111638
pubmed: 35361724
pmcid: 8970450
Zheng X, Jin Y, Xu T, Xu H, Zhu S. Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: A cohort study. Ren Fail. 2023;45:2199093.
doi: 10.1080/0886022X.2023.2199093
pubmed: 37051660
pmcid: 10120844
Cheng Y, Xiang Q, Cao T, Tang F, Chen J, Qi D, et al. Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients. Nephrol Dial Transplant. 2023;38:1567–70.
doi: 10.1093/ndt/gfad017
pubmed: 36662034
Yao B, Wei Y, Zhang S, Tian S, Xu S, Wang R, et al. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance. iScience. 2019;20:489–96.
doi: 10.1016/j.isci.2019.10.002
pubmed: 31655060
pmcid: 6806671
Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122:3035–43.
doi: 10.1172/JCI60047
pubmed: 22945636
pmcid: 3433956
Narasaki Y, Sohn P, Rhee CM. The interplay between thyroid dysfunction and kidney disease. Semin Nephrol. 2021;41:133–43.
doi: 10.1016/j.semnephrol.2021.03.008
pubmed: 34140092
pmcid: 8221115
Ng YY, Lin HD, Wu SC, Yang CY, Yang WC, Liou HH, et al. Impact of thyroid dysfunction on erythropoietin dosage in hemodialysis patients. Thyroid. 2013;23:552–61.
doi: 10.1089/thy.2011.0495
pubmed: 23189968